Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference

Detalhes bibliográficos
Autor(a) principal: Sousa‐Pinto, B
Data de Publicação: 2022
Outros Autores: Schünemann, HJ, Sá‐Sousa, A, Vieira, RJ, Amaral, R, Anto, JM, Klimek, L, Czarlewski, W, Mullol, J, Pfaar, O, Bedbrook, A, Brussino, L, Kvedariene, V, Larenas‐Linnemann, D, Okamoto, Y, Ventura, MT, Agache, I, Ansotegui, IJ, Bergmann, KC, Bosnic‐Anticevich, S, Brozek, J, Canonica, GW, Cardona, V, Carreiro‐Martins, P, Casale, T, Cecchi, L, Chivato, T, Chu, DK, Cingi, C, Costa, EM, Cruz, AA, Del Giacco, S, Devillier, P, Eklund, P, Fokkens, WJ, Gemicioglu, B, Haahtela, T, Ivancevich, JC, Ispayeva, Z, Jutel, M, Kuna, P, Kaidashev, I, Khaitov, M, Kraxner, H, Laune, D, Lipworth, B, Louis, R, Makris, M, Monti, R, Morais‐Almeida, M, Mösges, R, Niedoszytko, M, Papadopoulos, NG, Patella, V, Pham‐Thi, N, Regateiro, FS, Reitsma, S, Rouadi, PW, Samolinski, B, Sheikh, A, Sova, M, Todo‐Bom, A, Taborda‐Barata, L, Toppila‐Salmi, S, Sastre, J, Tsiligianni, I, Valiulis, A, Vandenplas, O, Wallace, D, Waserman, S, Yorgancioglu, A, Zidarn, M, Zuberbier, T, Fonseca, JA., Bousquet, J
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/4261
Resumo: Background: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., "real-world data"). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods: We assessed the MASK-air® app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80). Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines.
id RCAP_6fd1bd77a083ebf1c6c0ee90339be987
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/4261
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important DifferenceAllergen immunotherapy;Allergic rhinitisCo-medicationMultivariable mixed-effects modelReal-world dataHDE ALERBackground: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., "real-world data"). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods: We assessed the MASK-air® app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80). Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines.WileyRepositório do Centro Hospitalar Universitário de Lisboa Central, EPESousa‐Pinto, BSchünemann, HJSá‐Sousa, AVieira, RJAmaral, RAnto, JMKlimek, LCzarlewski, WMullol, JPfaar, OBedbrook, ABrussino, LKvedariene, VLarenas‐Linnemann, DOkamoto, YVentura, MTAgache, IAnsotegui, IJBergmann, KCBosnic‐Anticevich, SBrozek, JCanonica, GWCardona, VCarreiro‐Martins, PCasale, TCecchi, LChivato, TChu, DKCingi, CCosta, EMCruz, AADel Giacco, SDevillier, PEklund, PFokkens, WJGemicioglu, BHaahtela, TIvancevich, JCIspayeva, ZJutel, MKuna, PKaidashev, IKhaitov, MKraxner, HLaune, DLipworth, BLouis, RMakris, MMonti, RMorais‐Almeida, MMösges, RNiedoszytko, MPapadopoulos, NGPatella, VPham‐Thi, NRegateiro, FSReitsma, SRouadi, PWSamolinski, BSheikh, ASova, MTodo‐Bom, ATaborda‐Barata, LToppila‐Salmi, SSastre, JTsiligianni, IValiulis, AVandenplas, OWallace, DWaserman, SYorgancioglu, AZidarn, MZuberbier, TFonseca, JA.Bousquet, J2022-11-03T16:15:45Z20222022-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/4261engAllergy. 2022 Oct;77(10):3002-301410.1111/all.15371info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:46:05Zoai:repositorio.chlc.min-saude.pt:10400.17/4261Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:21:35.270400Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference
title Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference
spellingShingle Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference
Sousa‐Pinto, B
Allergen immunotherapy;
Allergic rhinitis
Co-medication
Multivariable mixed-effects model
Real-world data
HDE ALER
title_short Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference
title_full Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference
title_fullStr Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference
title_full_unstemmed Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference
title_sort Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference
author Sousa‐Pinto, B
author_facet Sousa‐Pinto, B
Schünemann, HJ
Sá‐Sousa, A
Vieira, RJ
Amaral, R
Anto, JM
Klimek, L
Czarlewski, W
Mullol, J
Pfaar, O
Bedbrook, A
Brussino, L
Kvedariene, V
Larenas‐Linnemann, D
Okamoto, Y
Ventura, MT
Agache, I
Ansotegui, IJ
Bergmann, KC
Bosnic‐Anticevich, S
Brozek, J
Canonica, GW
Cardona, V
Carreiro‐Martins, P
Casale, T
Cecchi, L
Chivato, T
Chu, DK
Cingi, C
Costa, EM
Cruz, AA
Del Giacco, S
Devillier, P
Eklund, P
Fokkens, WJ
Gemicioglu, B
Haahtela, T
Ivancevich, JC
Ispayeva, Z
Jutel, M
Kuna, P
Kaidashev, I
Khaitov, M
Kraxner, H
Laune, D
Lipworth, B
Louis, R
Makris, M
Monti, R
Morais‐Almeida, M
Mösges, R
Niedoszytko, M
Papadopoulos, NG
Patella, V
Pham‐Thi, N
Regateiro, FS
Reitsma, S
Rouadi, PW
Samolinski, B
Sheikh, A
Sova, M
Todo‐Bom, A
Taborda‐Barata, L
Toppila‐Salmi, S
Sastre, J
Tsiligianni, I
Valiulis, A
Vandenplas, O
Wallace, D
Waserman, S
Yorgancioglu, A
Zidarn, M
Zuberbier, T
Fonseca, JA.
Bousquet, J
author_role author
author2 Schünemann, HJ
Sá‐Sousa, A
Vieira, RJ
Amaral, R
Anto, JM
Klimek, L
Czarlewski, W
Mullol, J
Pfaar, O
Bedbrook, A
Brussino, L
Kvedariene, V
Larenas‐Linnemann, D
Okamoto, Y
Ventura, MT
Agache, I
Ansotegui, IJ
Bergmann, KC
Bosnic‐Anticevich, S
Brozek, J
Canonica, GW
Cardona, V
Carreiro‐Martins, P
Casale, T
Cecchi, L
Chivato, T
Chu, DK
Cingi, C
Costa, EM
Cruz, AA
Del Giacco, S
Devillier, P
Eklund, P
Fokkens, WJ
Gemicioglu, B
Haahtela, T
Ivancevich, JC
Ispayeva, Z
Jutel, M
Kuna, P
Kaidashev, I
Khaitov, M
Kraxner, H
Laune, D
Lipworth, B
Louis, R
Makris, M
Monti, R
Morais‐Almeida, M
Mösges, R
Niedoszytko, M
Papadopoulos, NG
Patella, V
Pham‐Thi, N
Regateiro, FS
Reitsma, S
Rouadi, PW
Samolinski, B
Sheikh, A
Sova, M
Todo‐Bom, A
Taborda‐Barata, L
Toppila‐Salmi, S
Sastre, J
Tsiligianni, I
Valiulis, A
Vandenplas, O
Wallace, D
Waserman, S
Yorgancioglu, A
Zidarn, M
Zuberbier, T
Fonseca, JA.
Bousquet, J
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Sousa‐Pinto, B
Schünemann, HJ
Sá‐Sousa, A
Vieira, RJ
Amaral, R
Anto, JM
Klimek, L
Czarlewski, W
Mullol, J
Pfaar, O
Bedbrook, A
Brussino, L
Kvedariene, V
Larenas‐Linnemann, D
Okamoto, Y
Ventura, MT
Agache, I
Ansotegui, IJ
Bergmann, KC
Bosnic‐Anticevich, S
Brozek, J
Canonica, GW
Cardona, V
Carreiro‐Martins, P
Casale, T
Cecchi, L
Chivato, T
Chu, DK
Cingi, C
Costa, EM
Cruz, AA
Del Giacco, S
Devillier, P
Eklund, P
Fokkens, WJ
Gemicioglu, B
Haahtela, T
Ivancevich, JC
Ispayeva, Z
Jutel, M
Kuna, P
Kaidashev, I
Khaitov, M
Kraxner, H
Laune, D
Lipworth, B
Louis, R
Makris, M
Monti, R
Morais‐Almeida, M
Mösges, R
Niedoszytko, M
Papadopoulos, NG
Patella, V
Pham‐Thi, N
Regateiro, FS
Reitsma, S
Rouadi, PW
Samolinski, B
Sheikh, A
Sova, M
Todo‐Bom, A
Taborda‐Barata, L
Toppila‐Salmi, S
Sastre, J
Tsiligianni, I
Valiulis, A
Vandenplas, O
Wallace, D
Waserman, S
Yorgancioglu, A
Zidarn, M
Zuberbier, T
Fonseca, JA.
Bousquet, J
dc.subject.por.fl_str_mv Allergen immunotherapy;
Allergic rhinitis
Co-medication
Multivariable mixed-effects model
Real-world data
HDE ALER
topic Allergen immunotherapy;
Allergic rhinitis
Co-medication
Multivariable mixed-effects model
Real-world data
HDE ALER
description Background: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., "real-world data"). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods: We assessed the MASK-air® app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80). Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines.
publishDate 2022
dc.date.none.fl_str_mv 2022-11-03T16:15:45Z
2022
2022-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/4261
url http://hdl.handle.net/10400.17/4261
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Allergy. 2022 Oct;77(10):3002-3014
10.1111/all.15371
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131310924496896